Phase I/II trial of nab-Paclitaxel,Carboplatin,plus Bevacizumab chemotherapy for patients with advanced Non-Squamous Non-Small Cell Lung Cancer.

Phase I/II trial of nab-Paclitaxel,Carboplatin,plus Bevacizumab chemotherapy for patients with advanced Non-Squamous Non-Small Cell Lung Cancer. - Phase I/II trial of nab-Paclitaxel,Carboplatin,plus Bevacizumab chemotherapy for patients with advanced Non-Squamous Non-Small Cell Lung Cancer.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013201

Enrollment

Registered

2014-02-19

Start date

2014-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Non-Squamous Non-Small Cell Lung Cancer

Interventions

Nab-Paclitaxel,Carboplatin,plus Bevacizumab chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients histologically or cytologically diagnosed advanced Non-Squamous Non-Small Cell Lung Cancer. ECOG Performanse status 0-1

Exclusion criteria

Exclusion criteria: The patients who have brain metastasis and have symptom or need therapy. The patients who have hemoptysis.

Design outcomes

Primary

Measure	Time frame
PhaseI:Dose Limiting Toxicity(DLT),Minimal Tolerated Dose(MTD),Recommended Dose(RD) PhaseII:Objective Response Rate(ORR)	—

Secondary

Measure	Time frame
PhaseI:Safety,Objective Response Rate(ORR),Progression Free Survival(PFS),Overall Survival(OS)	—

Countries

Japan

Contacts

Public ContactAtsushi Horiike

Cancer Institute Hospital of JFCR Department of Thoracic Medical oncology

atsushi.horiike@jfcr.or.jp03-3520-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026